Scripps Health

The Inner Circle acknowledges Lars R. Newsome, MD as a Pinnacle Life Member

Retrieved on: 
Wednesday, March 6, 2024

DELMAR, Calif., March 6, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Lars R. Newsome, MD is acknowledged as a Pinnacle Life Member for his contributions to the fields of Anesthesiology and Interventional Pain Management.

Key Points: 
  • DELMAR, Calif., March 6, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Lars R. Newsome, MD is acknowledged as a Pinnacle Life Member for his contributions to the fields of Anesthesiology and Interventional Pain Management.
  • The doctor is board certified in anesthesiology, pain management, critical care management, and transesophageal echocardiography.
  • Dr. Newsome is affiliated with the San Diego Spine and Orthopedic Center and works with Dr. Eric S. Korsh.
  • A pain management specialist is a doctor who specializes in pain medicine, focusing on the evaluation, treatment and prevention of pain.

Healcisio AI Reduces Sepsis Mortality By Nearly 20%: NIH Funded Healcisio Collaboration Advances the Development of AI Driven Diagnostic Tools

Retrieved on: 
Tuesday, January 23, 2024

Additionally, the AI driven notifications contributed to improvements in the Centers for Medicare & Medicaid Services (CMS) SEP-1 quality measure.

Key Points: 
  • Additionally, the AI driven notifications contributed to improvements in the Centers for Medicare & Medicaid Services (CMS) SEP-1 quality measure.
  • Healcisio is a healthcare technology startup based in La Jolla, CA, focused on bringing state-of-the-art AI-based diagnostic tools to the bedside.
  • The Healcisio AI evaluated in this study works by dynamically monitoring a patient's laboratory results, vital signs, medications, and comorbidities to detect sepsis before obvious clinical manifestations.
  • Healcisio received $257,723 in its first year of funding to deploy its AI and expand its pioneering work in predictive health analytics utilizing smart order-sets and active sensing.

NuView Life Sciences Announces the Appointments of Dr. Stanley J. Pappelbaum and A.J. Boechler to Board of Directors

Retrieved on: 
Wednesday, January 3, 2024

PARK CITY, Utah, Jan. 3, 2024 /PRNewswire/ -- NuView Life Sciences, Inc. ("NuView", the "company"), a radiopharmaceutical company seeking to enhance the global oncology market with its novel platform (NV-VPAC1™) capable of detecting and precisely targeting G protein-coupled receptors for cancer, announced the appointments of Dr. Stanley J. Pappelbaum and A.J. Boechler to its board of directors. Their combined experience and expertise developing, commercializing, and scaling therapeutics that span the product lifecycle adds further depth to NuView's leadership team as the Company advances its NV-VPAC1™ theranostic technology towards key clinical and commercialization milestones in 2024. NuView is leveraging its NV-VPAC1™ platform to advance a pipeline of precision in vitro laboratory diagnostics tests and in vivo cancer diagnostics and therapy delivery systems targeting multiple high-need, large-market indications, including prostate and bladder cancer.

Key Points: 
  • Boechler to its board of directors.
  • "On behalf of the Board, I am pleased to welcome Stan and A.J.
  • and look forward to benefitting from their knowledge and expertise," said Paul Crowe, Chairman and Chief Executive Officer of NuView.
  • Boechler joins the NuView board offering more than 30 years of executive leadership experience at the General Electric Company.

Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia

Retrieved on: 
Thursday, December 14, 2023

The first dose cohort consisted of a starting dose of 20 mg/m2, and there were no dose limiting toxicities.

Key Points: 
  • The first dose cohort consisted of a starting dose of 20 mg/m2, and there were no dose limiting toxicities.
  • The approved treatment cycle is two doses per week over four weeks for a total of eight doses administered over twenty-eight days.
  • The Phase 1b portion of the study is expected to commence after completion of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination with decitabine in refractory/relapsed AML patients.
  • Gail J. Roboz, M.D., is the National Principal Investigator for the Phase 1/1b trial.

Luna Designated CMS/Medicare "Exceptional Provider" for Second Consecutive Year

Retrieved on: 
Tuesday, December 5, 2023

NASHVILLE, Tennessee, Dec. 5, 2023 /PRNewswire/ -- Luna, the leading provider of in-home outpatient physical therapy, announced its designation today as an "Exceptional Provider" by the Centers for Medicare & Medicaid Services (CMS) for the second year in a row, according to the most recent update of its Merit-based Incentive Payment System (MIPS). MIPS, a pivotal component of Medicare's payment reform initiatives, seeks to enhance healthcare quality by linking payment adjustments to providers' performance on various quality and efficiency metrics.

Key Points: 
  • Over 80% of Luna patients experience significant pain and functional improvements, verified by CMS, the only federally approved standardized measure for outcomes.
  • Founded in 2018, Luna has more than doubled each year for the fifth consecutive year, making it the fastest-growing physical therapy clinic in the country.
  • Unlike remote or virtual care, Luna's licensed physical therapists provide 1:1 hands-on care in the convenience of the patient's home.
  • With Luna, patients can request in-home physical therapy via the Luna app .

Baylor College of Medicine teams with Luna to expand access to in-home, outpatient physical therapy services

Retrieved on: 
Tuesday, November 7, 2023

NASHVILLE, Tenn., Nov. 7, 2023 /PRNewswire/ -- Baylor College of Medicine , a renowned health sciences institution in Houston, Texas, has teamed up with Luna , the leading provider of in-home outpatient physical therapy, to expand access to patient services.

Key Points: 
  • NASHVILLE, Tenn., Nov. 7, 2023 /PRNewswire/ -- Baylor College of Medicine , a renowned health sciences institution in Houston, Texas, has teamed up with Luna , the leading provider of in-home outpatient physical therapy, to expand access to patient services.
  • Residents across Houston will have access to convenient, high-quality outpatient physical therapy in the safety and convenience of their own home.
  • "Patient access is a big concern for us, given our limited number of outpatient physical therapy clinics.
  • Working together with Luna allows Baylor to expand patient access to physical therapy and other specialities care without the need for additional brick-and-mortar locations," said Gayleen Breeding, administrator of orthopedic surgery at Baylor.

Ordr Continues Strong Commitment to Healthcare Industry with Appointment of Wes Wright as Chief Healthcare Officer

Retrieved on: 
Thursday, September 28, 2023

SANTA CLARA, Calif., Sept. 28, 2023 /PRNewswire/ -- Ordr, the leader in connected device security, announced that Wes Wright has joined the company as its new Chief Healthcare Office (CHO). Today's news highlights Ordr's continued commitment to providing healthcare organizations and security teams with the focused, industry-proven solutions needed to secure all connected devices and equipment, including Internet of Things (IoT), Internet of Medical Things (IoMT), operational technology (OT), and traditional IT systems.

Key Points: 
  • As Ordr's first CHO, Wes Wright is responsible for driving the company's engagements in the healthcare industry, including working with product teams to incorporate evolving customer needs into the Ordr platform.
  • His extensive background as a hospital and healthcare organization CTO and CIO will be invaluable to delivering the most trusted and effective connected device security solution in the healthcare industry.
  • "Wes will be a tremendous asset for Ordr and for our growing portfolio of healthcare customers.
  • Prior to joining Ordr, Wes was the CTO for digital identity company Imprivata, which had a large healthcare customer base.

Luna and Adventist Health partner to improve access to in-home, outpatient physical therapy across Los Angeles

Retrieved on: 
Tuesday, September 12, 2023

NASHVILLE, Tenn., Sept. 12, 2023 /PRNewswire/ -- Luna , the leading provider of in-home, in-person physical therapy, and Adventist Health Simi Valley, a nonprofit, integrated health system serving more than 80 communities on the West Coast, have today announced a partnership to improve access to in-home, in-person outpatient physical therapy across the greater Los Angeles area.

Key Points: 
  • NASHVILLE, Tenn., Sept. 12, 2023 /PRNewswire/ -- Luna , the leading provider of in-home, in-person physical therapy, and Adventist Health Simi Valley, a nonprofit, integrated health system serving more than 80 communities on the West Coast, have today announced a partnership to improve access to in-home, in-person outpatient physical therapy across the greater Los Angeles area.
  • Luna will provide Adventist Health with a seamless, coordinated solution for patients that improve access to outpatient physical therapy, and focus on quality, convenience, and delivery.
  • This partnership with Luna extends our vision, offering high-quality, in-home outpatient physical therapy beyond our facility's campus," said Jennifer Swenson, President, Adventist Health Simi Valley.
  • Leading health systems such as Providence, Emory Healthcare, Intermountain Healthcare, and Scripps Health have partnered with Luna to offer outpatient physical therapy in the convenience of a patient's home.

PrecisePK Celebrates 30 Years of Bayesian Precision Dosing Partnership With UC San Diego Health, Leading Other UC Hospitals To Follow

Retrieved on: 
Thursday, August 24, 2023

SAN DIEGO, Aug. 24, 2023 /PRNewswire/ -- Today, PrecisePK announces the celebration of the 30th anniversary of its partnership with UC San Diego Health.

Key Points: 
  • SAN DIEGO, Aug. 24, 2023 /PRNewswire/ -- Today, PrecisePK announces the celebration of the 30th anniversary of its partnership with UC San Diego Health.
  • This decades-long initiative has proven the success of using Bayesian precision dosing to improve patient outcomes.
  • With other UC hospitals joining, PrecisePK is delivering state-of-the-art Bayesian therapeutic drug monitoring technology to a total of 9 prominent sites.
  • PrecisePK and UCSD Health mark 30 years of partnership in vancomycin AUC precision dosing, leading others to follow.

HealthTrust University Conference Attracts Record Number of Healthcare Leaders, Exhibitors, and Education Experts

Retrieved on: 
Thursday, August 17, 2023

HealthTrust Performance GroupSM , a leading healthcare performance improvement organization, reported record engagement on the part of members, suppliers, and subject matter experts during the recently concluded HealthTrust University (HTU) Conference in Las Vegas, Nevada.

Key Points: 
  • HealthTrust Performance GroupSM , a leading healthcare performance improvement organization, reported record engagement on the part of members, suppliers, and subject matter experts during the recently concluded HealthTrust University (HTU) Conference in Las Vegas, Nevada.
  • HealthTrust executives and leading experts in healthcare and supply chain emphasized best practices to optimize outcomes for patients and communities served by HealthTrust member organizations.
  • Approximately 3,500 attendees participated in the conference that took place July 17-19 at Mandalay Bay Convention Center.
  • More than 100 subject matter experts led education sessions—most with Continuing Education credits—and micro-sessions covering topics on oncology and biologics, value analysis, purchased services, and more.